Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive into the world of biotech with fresh insights, sharp analysis, and the stories that are shaping the future of health. Whether you’re an industry insider, an investor, or just biotech-curious, we’ve got something for you.
We are now publishing 7x per week according to the following cadence:
Mondays: BioBucks: Stock Analysis & Biotech Catalysts
Tuesdays: X-article on biotech hot topics
Wednesdays: Podcast format of X-article
Thursdays: Insiders Track: Public & Private Biotech Markets
Fridays: Sweat Equity: Your Weekly Biotech Fix
Saturdays: Podcast format of Weekly News Update
Sundays: Building Biotech: Strategic Topics
SUBSCRIBE TO PODCAST HERE:
Please help spread the work by subscribing and hitting the share button if you are enjoying content!
Welcome to the Bowtied Biotech Podcast, where we explore the cutting edge of science and innovation shaping the future of healthcare. In this episode, we delve into the recent wave of transformation sweeping the biotech landscape, featuring the groundbreaking merger between Chroma Medicine and Nvelop Therapeutics to create nChroma Bio. With $75 million in new funding, the combined entity is set to revolutionize genetic medicine, uniting Chroma's expertise in epigenetic editing with Nvelop's delivery platforms. We'll also tackle the industry's shifting tides, from Editas Medicine's pivot toward in vivo gene editing amidst layoffs to Keros Therapeutics' unexpected clinical setbacks. Plus, we’ll highlight promising advances in Alzheimer's therapies and hear how M&A trends are reshaping pharma's strategic priorities. Stay tuned for an exciting dive into biotech’s biggest stories and their implications for science, business, and patient care.
📣🎙️ TODAY’S POCAST:
[ 0:00 ] Intro
[ 1:01 ] Gene Editing: Chroma & Nvelop Merge
[ 2:12 ] $EDIT Layoffs & Strategic Shift
[ 3:03 ] $KROS Setback
[ 3:49 ] $NAMS Unexpected Cholesterol Drug Breakthrough
[ 4:37 ] 2024 Election and Biotech Policy Shifts
[ 6:58 ] IPO Window Status
[ 7:43 ] Pharma M&A Landscape: $NVO $LLY
[ 9:30 ] Radiopharma: The Hottest Show in Oncology
[10:25 ] GLP-1 Agonists for Alzheimer's
[12:00 ] Gene Therapy Challenges & Opportunities
[15:13 ] Ethical Considerations in Biotech
[15:49 ] Wrap-Up and Reflections
CONCLUSION
We hope you are enjoying our first leap into the podcast world! Instead of waiting until everything is perfect, we’re diving in and will continue improving as we go. Feel free to send us your suggestions, feedback, or constructive criticism—we’d love to hear from you!
As a reminder, if looking to go deeper into the topics we cover check out our website BowTiedBiotech.com, or DM us on twitter, or email us: bowtiedbiotech@gmail.com
ABOUT BOWTIEDBIOTECH
As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients. Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.
DISCLAIMER
None of this is to be deemed legal or financial advice of any kind. All updates are sourced from publicly available disclosures. Insights are *opinions* written by an anonymous cartoon/scientist/investor.
TOP BOWTIEDBIOTECH NEWSLETTERS
Share this post